AU2015364253B2 - Synergistic co-administration of computationally optimized broadly reactive antigens for H1N1 influenza - Google Patents

Synergistic co-administration of computationally optimized broadly reactive antigens for H1N1 influenza Download PDF

Info

Publication number
AU2015364253B2
AU2015364253B2 AU2015364253A AU2015364253A AU2015364253B2 AU 2015364253 B2 AU2015364253 B2 AU 2015364253B2 AU 2015364253 A AU2015364253 A AU 2015364253A AU 2015364253 A AU2015364253 A AU 2015364253A AU 2015364253 B2 AU2015364253 B2 AU 2015364253B2
Authority
AU
Australia
Prior art keywords
influenza
seq
polypeptide
amino acid
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2015364253A
Other languages
English (en)
Other versions
AU2015364253A1 (en
Inventor
Tim ALEFANTIS
Donald Martin Carter Jr.
Christopher Austin Darby
Harold Kleanthous
Ted Milburn ROSS
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SANOFI PASTEUR Inc
Oregon Health & Science University
Original Assignee
SANOFI PASTEUR Inc
Oregon Health & Science University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SANOFI PASTEUR Inc, Oregon Health & Science University filed Critical SANOFI PASTEUR Inc
Publication of AU2015364253A1 publication Critical patent/AU2015364253A1/en
Application granted granted Critical
Publication of AU2015364253B2 publication Critical patent/AU2015364253B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16123—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AU2015364253A 2014-12-19 2015-12-18 Synergistic co-administration of computationally optimized broadly reactive antigens for H1N1 influenza Ceased AU2015364253B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462094772P 2014-12-19 2014-12-19
US62/094,772 2014-12-19
PCT/US2015/066882 WO2016100922A1 (en) 2014-12-19 2015-12-18 Synergistic co-administration of computationally optimized broadly reactive antigens for h1n1 influenza

Publications (2)

Publication Number Publication Date
AU2015364253A1 AU2015364253A1 (en) 2017-06-29
AU2015364253B2 true AU2015364253B2 (en) 2020-01-23

Family

ID=56127736

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2015364253A Ceased AU2015364253B2 (en) 2014-12-19 2015-12-18 Synergistic co-administration of computationally optimized broadly reactive antigens for H1N1 influenza

Country Status (7)

Country Link
US (2) US10220086B2 (enExample)
EP (1) EP3233116A4 (enExample)
JP (2) JP6764408B2 (enExample)
CN (1) CN107530417A (enExample)
AU (1) AU2015364253B2 (enExample)
CA (1) CA2970158A1 (enExample)
WO (1) WO2016100922A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3233116A4 (en) * 2014-12-19 2018-05-30 Oregon Health & Science University Synergistic co-administration of computationally optimized broadly reactive antigens for h1n1 influenza
WO2019086463A1 (en) 2017-10-30 2019-05-09 Baxalta GmbH Environmentally compatible detergents for inactivation of lipid-enveloped viruses
US20190167738A1 (en) * 2017-12-01 2019-06-06 Kemin Industries, Inc. Compositions containing euglena gracilis for viral protection and related methods
EP3773709A4 (en) 2018-03-28 2021-12-29 Sanofi Pasteur Inc. Methods of generating broadly protective vaccine compositions comprising neuraminidase
WO2020092207A1 (en) * 2018-10-28 2020-05-07 University Of Georgia Research Foundation Broadly reactive immunogens of influenza virus, compositions, and methods of use thereof
AU2022289009A1 (en) * 2021-06-10 2023-12-14 University Of Georgia Research Foundation, Inc. Broadly reactive viral antigens as immunogens, compositions and methods of use thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100221284A1 (en) * 2001-05-30 2010-09-02 Saech-Sisches Serumwerk Dresden Novel vaccine composition
DE102010018462A1 (de) 2009-04-27 2011-04-07 Novartis Ag Impfstoffe zum Schutz gegen Influenza
MX345150B (es) * 2012-03-30 2017-01-18 Univ Of Pittsburgh - Of The Commonwealth System Of Higher Education Antigenos ampliamente reactivos computacionalmente optimizados para virus de influenza h5n1 y h1n1.
IN2015DN03070A (enExample) * 2012-11-27 2015-10-02 Univ Pittsburgh
JP2016509015A (ja) 2013-02-11 2016-03-24 ノババックス，インコーポレイテッド 呼吸器合胞体ウイルス及びインフルエンザ用の混合ワクチン
EP3233116A4 (en) * 2014-12-19 2018-05-30 Oregon Health & Science University Synergistic co-administration of computationally optimized broadly reactive antigens for h1n1 influenza
US10927151B2 (en) 2015-06-09 2021-02-23 Sanofi Pasteur Inc. Methods of optimizing nucleotide sequences encoding engineered influenza proteins
US20200237898A1 (en) * 2015-09-21 2020-07-30 Oregon Health & Science University Vaccines intelligently produced by epitope recombination (viper) for influenza

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
B. M. GILES ET AL, A Computationally Optimized Hemagglutinin Virus-Like Particle Vaccine Elicits Broadly Reactive Antibodies that Protect Nonhuman Primates from H5N1 Infection, THE JOURNAL OF INFECTIOUS DISEASES, 2012, vol. 205(10), pg 1562 *

Also Published As

Publication number Publication date
WO2016100922A1 (en) 2016-06-23
US20190175721A1 (en) 2019-06-13
EP3233116A1 (en) 2017-10-25
CA2970158A1 (en) 2016-06-23
CN107530417A (zh) 2018-01-02
US20170368164A1 (en) 2017-12-28
JP6764408B2 (ja) 2020-09-30
JP2020186252A (ja) 2020-11-19
AU2015364253A1 (en) 2017-06-29
US10220086B2 (en) 2019-03-05
JP2018501258A (ja) 2018-01-18
US10925957B2 (en) 2021-02-23
EP3233116A4 (en) 2018-05-30

Similar Documents

Publication Publication Date Title
WO2016100926A8 (en) Synergistic co-administration of computationally optimized broadly reactive antigens for human and avian h5n1 influenza
AU2015286723B2 (en) Influenza virus vaccines and uses thereof
AU2015286721B2 (en) Influenza virus vaccines and uses thereof
MX2020013153A (es) Metodos y composiciones para inducir inmunidad protectora contra la infeccion por virus de inmunodeficiencia humana.
EP4691484A3 (en) Influenza mrna vaccines
MX2021006931A (es) Antigenos del virus de la inmunodeficiencia humana, vectores, composiciones y metodos de uso de estos.
MX2021001053A (es) Vacunas contra virus de la influenza y sus usos.
MX2012009581A (es) Vacunas para su uso en la profilaxis y tratamiento de la enfermedad del virus de influenza.
PH12019501569A1 (en) Universal influenza vaccine compositions
PH12014500369A1 (en) Influenza h5 vaccines
NZ739260A (en) Inactivated canine influenza vaccines and methods of making and uses thereof
MY183072A (en) Methods and compositions for inducing protective immunity against filovirus infection
EP3939604A3 (en) Influenza hemagglutinin protein vaccines
WO2015195218A8 (en) Polyvalent influenza virus-like particles (vlps) and use as vaccines
MX2017003928A (es) Composiciones farmaceuticas de accion prolongada.
EA201290897A1 (ru) Вакцины для пандемического гриппа
EP3233116A4 (en) Synergistic co-administration of computationally optimized broadly reactive antigens for h1n1 influenza
EP3599247A3 (en) Recombinant hemagglutinin protein of influenza virus and vaccine containing the same
MX2015010763A (es) Proteinas h5 del virus de la gripe h5n1 para uso como un medicamento.
IL259451A (en) Live virus with accumulation of dengue fever of a weakened nature and vaccination of dengue fever containing identical antigens
ZA201700164B (en) Influenza virus vaccines and uses thereof
HK40013539A (en) Signature-based human immunodeficiency virus (hiv) envelope (env) trimer vaccines and methods of using the same
HK1173963A (en) Vaccines for pandemic influenza
HK1179177A (en) Vaccines for use in the prophylaxis and treatment of influenza virus disease

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired